Fig. 2: Intervention cost threshold analysis from the health care payer's perspective (all-inclusive cost per dose), comparing 5 strategies to no intervention and to each other, at a willingness to pay of €35,000 per QALY gained. | npj Vaccines

Fig. 2: Intervention cost threshold analysis from the health care payer's perspective (all-inclusive cost per dose), comparing 5 strategies to no intervention and to each other, at a willingness to pay of €35,000 per QALY gained.

From: Cost-effectiveness of maternal vaccine and/or monoclonal antibody strategies against respiratory syncytial virus in Belgian infants

Fig. 2: Intervention cost threshold analysis from the health care payer's perspective (all-inclusive cost per dose), comparing 5 strategies to no intervention and to each other, at a willingness to pay of €35,000 per QALY gained.

Y-axis: maternal vaccine costs ranged from €50-€30, X-axis: mAb costs from €50–€850. Each colour indicates a preferred RSV strategy, with the greatest uncertainty at the boundaries where strategies change. EUR euro, QALY quality-adjusted life-year, MV year-round maternal vaccine, MV Sept-Mar: seasonal maternal vaccine from September to March, NmAb: Oct-Mar seasonal NmAb strategy from October to March, NmAb: Oct-Mar + catch-up seasonal NmAb combined with a catch-up strategy.

Back to article page